ALBIREO PHARMA,INC. (NASDAQ:BIOD) Files An 8-K Other Events

Item8.01 Other Events

On May23, 2017, Albireo Pharma, Inc. (the Company) issued a press
release announcing the commencement of an underwritten public
offering of its common stock to a shelf registration statement
filed on Form S-3 (File No.333-215263) with the Securities and
Exchange Commission, which was declared effective on January10,
2017. In connection with the offering, the Company also announced
its intention to grant the underwriters an option for a period of
up to 30 days to purchase up to an additional 15% of the number
of shares of common stock sold in the offering on the same terms
and conditions. A copy of the press release is attached hereto as
Exhibit 99.1 and is incorporated herein by reference.

On May23, 2017, the Company filed with the Securities and
Exchange Commission a preliminary prospectus supplement to its
effective shelf registration statement on Form S-3 (the
Preliminary Prospectus Supplement) to Rule 424 under the
Securities Act of 1933, as amended, relating to the
aforementioned proposed public offering of shares of the Companys
common stock. The Preliminary Prospectus Supplement contains an
updated summary description of the Companys business in the
section entitled Prospectus Supplement Summary, which is attached
hereto as Exhibit 99.2 and incorporated herein by reference, and
contains supplemental risk factors in the section entitled Risk
Factors, which is attached hereto as Exhibit 99.3 and
incorporated herein by reference.

This Current Report on Form 8-K, including the exhibits hereto,
shall not constitute an offer to sell or the solicitation of an
offer to buy any securities of the Company, which is being made
only by means of a written prospectus meeting the requirements of
Section10 of the Securities Act of 1933, as amended, nor shall
there be any sale of the Companys securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of such jurisdiction.

Item9.01 Financial Statements and Exhibits.

(d) Exhibits

About ALBIREO PHARMA, INC. (NASDAQ:BIOD)

Albireo Pharma, Inc., formerly Biodel Inc., is a specialty biopharmaceutical company. It is focused on the development and commercialization of bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI), disorders where improper flow or absorption of bile causes serious medical conditions for which there is unmet need. The target indication for its lead product candidate, A4250, is progressive familial intrahepatic cholestasis (PFIC), which is a genetic disorder affecting children. A4250 is being evaluated in a Phase II clinical trial. Other products in the Company’s pipeline include Elobixibat, A3384 and Bile Acid Modulators. Elobixibat is indicated for the treatment of chronic constipation and it has completed its Phase III clinical trials. A3384 is a formulation of cholestyramine that is designed to release cholestyramine directly in the colon. It has completed a Phase II clinical trial of a prior formulation of A3384 in bile acid malabsorption (BAM).

ALBIREO PHARMA, INC. (NASDAQ:BIOD) Recent Trading Information

ALBIREO PHARMA, INC. (NASDAQ:BIOD) closed its last trading session 00.00 at 19.46 with 2,338,156 shares trading hands.